Compare VYGR & STRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | STRS |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 238.1M |
| IPO Year | 2015 | 1994 |
| Metric | VYGR | STRS |
|---|---|---|
| Price | $3.81 | $28.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 511.1K | 26.8K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 512.50 |
| EPS | N/A | ★ 0.82 |
| Revenue | $10,135,000.00 | ★ $29,914,000.00 |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | ★ N/A | $35.24 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.65 | $15.35 |
| 52 Week High | $5.55 | $32.93 |
| Indicator | VYGR | STRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 42.23 |
| Support Level | $3.71 | $28.22 |
| Resistance Level | $4.39 | $31.62 |
| Average True Range (ATR) | 0.27 | 0.68 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 40.23 | 37.35 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.